Skip to content ↓

Daley of Whitehead will discuss science of stem cells

What are the different types of stem cells? Where do we stand in developing the promise of embryonic stem cells into therapies for patients? Hear some answers from Dr. George Daley of the MIT/Whitehead Institute for Biomedical Research and Massachusetts General Hospital.

Daley, a leading investigator in the development of stem cell therapies for blood disorders, will give a talk titled "Stem Cells: Medicine and Myth" today (Sept. 12) at 4:30 p.m. in Room 54-100.

Daley's work ranges from the basic science of embryonic and adult stem cells to the technological issues of making stem cells a therapeutic reality in clinical practice. He has served as an advisor to the federal government and has played an active role in the development of public policy for stem cell research.

Professor Douglas Lauffenburger, director of MIT's Biotechnology Process Engineering Center (BPEC), will introduce the lecture, providing the context for Daley's research at MIT.

Daley is a Fellow at the Whitehead Institute, a BPEC investigator and an assistant professor of medicine at MGH. The talk is hosted by the MIT student chapter of the Biomedical Engineering Society (BMES). It is part of the BMES-BPEC Distinguished Lecture Series.

A version of this article appeared in MIT Tech Talk on September 12, 2001.

Related Topics

More MIT News

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story